Tonix Pharmaceuticals Holding Corp

Tonix insiders buy 22,700 options at zero cost, showing confidence in upcoming clinical milestones that could boost share price and unlock upside for shareholders.

Tonix Pharmaceuticals CEO buys 15,000 shares, signaling confidence amid preclinical oncology data and a bullish insider‑buying trend that could boost valuation.

Tonix insider option purchases signal confidence as CNS drug pipeline—TNX‑102 & TNX‑201—faces FDA review; investors should track clinical milestones and regulatory decisions for potential upside.